Tvardi Therapeutics: Tweardy Discloses 3.4% Stake in 13G/A
Schedule 13G/A (Amendment 1) discloses the current ownership of Tvardi Therapeutics, Inc. (TVRD) by Samuel D. Tweardy.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Schedule 13G/A (Amendment 1) discloses the current ownership of Tvardi Therapeutics, Inc. (TVRD) by Samuel D. Tweardy.
The filer reports 315,658 common shares, held via the Samuel David Tweardy 2020 Gift Trust, representing 3.4 % of the 9,373,433 shares outstanding as of 8 Aug 2025. He retains sole voting and dispositive power over the entire stake; no shared power is indicated.
Tweardy resigned as trustee of two related 2020 Gift Trusts—actions permitted under an existing 17 Dec 2024 lock-up agreement—so those trusts’ shares are no longer included in his beneficial ownership. Item 5 confirms the position is now 5 % or less of the class, qualifying the filing for passive Schedule 13G treatment. The certification states the shares were not acquired to influence control of the issuer.
Insights
TL;DR – Tweardy now owns 3.4 % of TVRD, below the 5 % threshold; impact on control or float is minimal.
This 13G/A signals that Samuel D. Tweardy’s beneficial ownership has fallen under the 5 % reporting line, reducing his classification from a large to a sub-5 % passive holder. All 315,658 shares are subject to a lock-up, so near-term trading impact is limited. Because no change-of-control intent is declared and no voting agreements exist, governance implications appear neutral. Overall market impact should be modest, though awareness of the reduced insider concentration may slightly improve perceived float liquidity.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why was a Schedule 13G/A filed on 5 Aug 2025?
What is Tvardi Therapeutics’ CUSIP number?
Where is Tvardi Therapeutics headquartered?
AI-generated analysis. How Rhea-AI works. Not financial advice.